Welcome
The BCLC at the Hospital Clínic of Barcelona is a multidisciplinary team involving all relevant medical specialities devoted to clinical care, research and education in the field of liver cancer. It combines state of the art diagnosis and therapy, with the development of several research projects to evaluate new treatment options. These include laboratory studies in cell cultures or animal models and clinical trials in patients with liver cancer.


Recent Publications

JOURNAL ARTICLE
Diagnostic performance of contrast-enhanced US in small liver nodules not conclusively characterized after MRI in cirrhotic patients

Saborido B, Darnell A, Forner A, García-Criado Á, Díaz A, Ayuso C, Vilana R, Bruix J, Reig M, Rimola J.

2025;10.1007/s00330-025-11495-3
Pubmed abstract
JOURNAL ARTICLE
Cardiological adverse events in hepatocellular carcinoma patients receiving immunotherapy: Influence of comorbidities and clinical outcomes

Fortuny M, García-Calonge M, Arrabal Ó, Sanduzzi-Zamparelli M, Castaño-García A, Cascos E, Mesa A, Piedra-Cerezal AM, Llarch N, Iserte G, Campos M, González M, Marsal A, Lorca R, Rodríguez M, Torres F, Varela M, Reig M.

2025;10.1016/j.ejca.2025.115404
Pubmed abstract
JOURNAL ARTICLE
Evolving epidemiology of HCC in Spain

Sala M, Pascual S, Rota Roca MR, Matilla AM, Campos M, Delgado M, Ferrer MT, Montero JL, González-Santiago JM, Guerrero A, Aracil C, Rodríguez-Lope C, Romero-Gutiérrez M, Sogbe M, Vázquez-Rodríguez S, Olmo JF, Mínguez B, Cortés-García L, Vallejo-Senra N, Unceta PR, Clos A, Díaz-Bethencourt D, Sánchez AG, Castro RQ, Bustamante J, Perelló C, Urquijo Ponce JJ, Serra HA, Llamoza-Torres CJ, Montoliu S, Fernández-Marcos C, Guiberteau A, Hernández-Guerra M, Vergara M, Fernández-López AM, Valer López-Fando MP, Gutiérrez-García ML, Hernáez-Alsina T, Coll S, Cuyás B, Morillas MJ, Olmedo SR, Fernández-Bermejo M, Roget M, Ramos IC, Pacheco Del Río G, Rifà R, Gacho PC, Barrio ML, Gómez-Rubio M, Peñas I, Serra I, Cachero A, Reig M, Giraldez Á, Guerrero M, Segarra JX, Lledó JL, Díaz-González Á, Delgado C, Iñarrairaegui M, Rodríguez-González MM, Lázaro M, Bermúdez-Ramos M, Lué A, Molina E, Macías-Rodríguez MA, Rodríguez M, Chiminazzo V, Varela M.

2025;10.1016/j.jhepr.2025.101336
Pubmed abstract
JOURNAL ARTICLE
Health-related quality of life in patients with unresectable hepatocellular carcinoma treated with SIRT and nivolumab: a sub-analysis of the NASIR-HCC trial

De la Torre-Aláez M, Matilla A, Varela M, Iñarrairaegui M, Reig M, Lledó JL, Arenas JI, Lorente S, Testillano M, Márquez L, Iserte G, Argemí J, Gómez-Martin C, Rodríguez-Fraile M, Bilbao JI, Pollock RF, Pöhlmann J, Agirrezabal I, Sangro B.

2025;10.1186/s41687-025-00873-6
Pubmed abstract
JOURNAL ARTICLE
The 2024 ILTS-ILCA consensus recommendations for liver transplantation for hepatocellular carcinoma and intrahepatic cholangiocarcinoma

Kodali S, Kulik L, D'Allessio A, De Martin E, Hakeem AR, Lewinska M, Lindsey S, Liu K, Maravic Z, Patel MS, Pinato D, Rammohan A, Rich N, Sanduzzi Zamparelli M, Victor DW 3rd, Vinaxia C, Brombosz EW, Villanueva A, Meyer T, Selzner N, Ghobrial RM, Rela M, Sapisochin G.

2025;10.1097/LVT.0000000000000589
Pubmed abstract
JOURNAL ARTICLE
Transarterial chemoembolization with doxorubicin-loaded radiopaque microspheres for hepatocellular carcinoma: safety, efficacy and distribution.

A. Páez-Carpio, P. Bermúdez, M. Sanduzzi Zamparelli, M. Barrufet, O. Arrabal, A. Forner, A. Darnell, J. Bruix, F. Torres, M. Reig, M. Burrel,

2025;10.1016/j.rx.2025.01.001.
Pubmed abstract
JOURNAL ARTICLE
Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours. Melero I, de Miguel Luken M, de Velasco G, Garralda E, Martín-Liberal J, Joerger M, Alonso G, Goebeler ME, Schuler M, König D, Dummer R, Reig M, Rodriguez Ruiz ME, Calvo E, Esteban-Villarrubia J, Oberoi A, Sabat P, Soto-Castillo JJ, Koster KL, Saavedra O, Sayehli C, Gromke T, Läubli H, Ramelyte E, Fortuny M, Landa-Magdalena A, Moreno I, Torres-Jiménez J, Hernando-Calvo A, Hess D, Racca F, Richly H, Schmitt AM, Eggenschwiler C, Sanduzzi-Zamparelli M, Vilalta-Lacarra A, Trojan J, Koch C, Galle PR, Foerster F, Trajanoski Z, Hackl H, Gogolla F, Koll FJ, Wild P, Chun FKH, Reis H, Lloyd P, Machacek M, Gajewski TF, Fridman WH, Eggermont AMM, Bargou R, Schöniger S, Rüschoff J, Tereshchenko A, Zink C, da Silva A, Lichtenegger FS, Akdemir J, Rüdiger M, L'Huillier P, Dutta A, Haake M, Auckenthaler A, Gjorgjioska A, Rössler B, Hermann F, Liebig M, Reichhardt D, Schuberth-Wagner C, Wischhusen J, Fettes P, Auer M, Klar K, Leo E. Nature 2024;10.1038/s41586-024-08305-z
Pubmed abstract
JOURNAL ARTICLE
Genome-wide DNA methylation markers associated with metabolic liver cancer. Antwi SO, Siaw ADJ, Armasu SM, Frank JA, Yan IK, Ahmed FY, Izquierdo-Sanchez L, Boix L, Rojasti A, Banales JM, Reig M, Stål P, Romero Gómez M, Wangensteen KJ, Singal AG, Roberts LR, Patel T. medRxiv . 2024;10.1101/2024.11.15.24317378.
Pubmed abstract
JOURNAL ARTICLE
Utilizing a domain-specific large language model for LI-RADS v2018 categorization of free-text MRI reports: a feasibility study. Matute-González M, Darnell A, Comas-Cufí M, Pazó J, Soler A, Saborido B, Mauro E, Turnes J, Forner A, Reig M, Rimola J.Insights Imaging. 2024;10.1186/s13244-024-01850-1.
Pubmed abstract
JOURNAL ARTICLE
Early hepatic decompensation identifies patients with hepatocellular carcinoma treated with Atezolizumab plus Bevacizumab or Sorafenib at highest risk of death. Cabibbo G, Celsa C, Battaglia S, Enea M, Di Maria G, Grova A, Ciccia R, Manfredi GF, Iavarone M, Vogel A, Singal AG, Reig M, Pinato DJ, Cammà C.Clin Cancer Res.  2024;10.1158/1078-0432.CCR-24-2582.
Pubmed abstract
JOURNAL ARTICLE
Rare primary liver cancers: An EASL position paper. Wege H, Campani C, de Kleine R, Meyer T, Nault JC, Pawlik TM, Reig M, Ricke J, Sempoux C, Torzilli G, Zucman-Rossi J.J Hepatol. 2024;10.1016/j.jhep.2024.06.004.
Pubmed abstract
JOURNAL ARTICLE
Outcomes in the Asian subgroup of the phase III randomised HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. Lau G, Abou-Alfa GK, Cheng AL, Sukeepaisarnjaroen W, Van Dao T, Kang YK, Thungappa SC, Kudo M, Sangro B, Kelley RK, Furuse J, Park JW, Sunpaweravong P, Fasolo A, Yau T, Kawaoka T, Azevedo S, Reig M, Assenat E, Yarchoan M, He AR, Makowsky M, Gupta C, Negro A, Chan SL.J Hepatol. 2024;10.1016/j.jhep.2024.07.017
Pubmed abstract
JOURNAL ARTICLE
Incidence of Liver and Non-liver Cancers After Hepatitis C Virus Eradication: A Population-Based Cohort Study. Ríos J, Sapena V, Mariño Z, Bruix J, Forns X, Morros R, Reig M, Torres F, Pontes C. Drugs Real World Outcomes. 2024;10.1007/s40801-024-00437-y.
Pubmed abstract
JOURNAL ARTICLE
Dynamic changes in immune cell populations by AXL kinase targeting diminish liver inflammation and fibrosis in experimental MASH. Grøndal SM, Tutusaus A, Boix L, Reig M, Blø M, Hodneland L, Gausdal G, Jackson A, Garcia de Frutos P, Lorens JB, Morales A, Marí M. Front Immunol. 2024;10.3389/fimmu.2024.1400553.
Pubmed abstract